---
title: "Shattuck Labs to Join Piper Sandler Virtual Novel Targets in Immunology Symposium"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/275132543.md"
datetime: "2026-02-06T13:30:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275132543.md)
  - [en](https://longbridge.com/en/news/275132543.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275132543.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/275132543.md) | [繁體中文](https://longbridge.com/zh-HK/news/275132543.md)


# Shattuck Labs to Join Piper Sandler Virtual Novel Targets in Immunology Symposium

Shattuck Labs Inc., a clinical-stage biotechnology company specializing in novel therapeutics for inflammatory and immune-mediated diseases, will participate in a fireside chat at the Piper Sandler Virtual Novel Targets in Immunology Symposium on February 12, 2026, at 2:00 PM ET. The company’s CEO Taylor Schreiber, M.D., Ph.D., CFO Andrew R. Neill, and Vice President of Clinical Development Michael Choi, M.D., will represent Shattuck Labs during the event. A replay of the prerecorded presentation will be available on the Events and Presentations section of Shattuck Labs’ website starting at 2:00 PM ET on February 12, 2026, and will be archived for up to 30 days following the presentation date. A webcast link is provided: HERE. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shattuck Labs Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9650089-en) on February 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/en/quote/IBBQ.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [Shattuck Labs, Inc. (STTK.US)](https://longbridge.com/en/quote/STTK.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)

## Related News & Research

- [BUZZ-MiNK Therapeutics rises as it wins funding for child cancer cell therapy](https://longbridge.com/en/news/278530484.md)
- [FDA approves GSK’s Wellcovorin for cerebral folate deficiency](https://longbridge.com/en/news/278697677.md)
- [AbbVie reports topline data from Phase I ABBV-295 trial](https://longbridge.com/en/news/278540526.md)
- [BioMarin Pharmaceutical Highlights Growth Plan, VOXZOGO Milestones, and Amicus Deal at Conference](https://longbridge.com/en/news/279015256.md)
- [Allogene Therapeutics Faces Trial Setback as ALLO-647 Halt Raises Lymphodepletion and Regulatory Timeline Risks](https://longbridge.com/en/news/279113385.md)